Skip to main content
Premium Trial:

Request an Annual Quote

Life Technologies Acquires BAC

NEW YORK (GenomeWeb News) – Life Technologies today announced that it has acquired Dutch firm BAC BV for an undisclosed sum.

BAC makes protein purification products and will expand Life Tech's portfolio in bioprocessing by adding the firm's affinity ligands to Life Tech's Poros brand of chromatography resins for purification of therapeutic products. The new technologies also complement Life Tech's Gibco brand of cell culture media products and the Applied Biosystems SEQ rapid molecular kits for containment and impurity testing of biotherapeutic products.

"Combining BAC's current portfolio and pipeline with our pre-existing portfolio expands Life's product offering and enables us to compete more fully across the protein purification market," Tony Hunt, head of BioProduction at Life Technologies, said in a statement. "We intend to immediately integrate the portfolios and leverage the Life commercial platform to drive accelerated growth in this market."

Life Tech said the deal is expected to be neutral to its overall return on invested capital three years after close.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.